| Entry |
| ||||||
|---|---|---|---|---|---|---|---|
| Name | Lusutrombopag (JAN/USAN/INN); Mulpleta (TN) | ||||||
| Product | MULPLETA (SHIONOGI) | ||||||
| Formula | C29H32Cl2N2O5S | ||||||
| Exact mass | 590.1409 | ||||||
| Mol weight | 591.5458 | ||||||
| Structure |  | ||||||
| Class | Metabolizing enzyme substrate DG02978 CYP4A11 substrate | ||||||
| Remark |
| ||||||
| Efficacy | Antithrombocytopenia, Thrombopoietin receptor agonist | ||||||
| Disease | Thrombocytopenia [DS:H00978] | ||||||
| Target | MPL (TPOR, CD110) [HSA:4352] [KO:K05082] | ||||||
| Pathway |
| ||||||
| Metabolism | Enzyme: CYP4A11 [HSA:1579] | ||||||
| Brite | Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] B BLOOD AND BLOOD FORMING ORGANS B02 ANTIHEMORRHAGICS B02B VITAMIN K AND OTHER HEMOSTATICS B02BX Other systemic hemostatics B02BX07 Lusutrombopag D10476 Lusutrombopag (JAN/USAN/INN) <JP/US> USP drug classification [BR:br08302] Blood Products and Modifiers Blood Products and Modifiers, Other Blood Products and Modifiers, Micellaneous Lusutrombopag D10476 Lusutrombopag (JAN/USAN/INN) Therapeutic category of drugs in Japan [BR:br08301] 3 Agents affecting metabolism 33 Blood and body fluid agents 339 Miscellaneous 3399 Others D10476 Lusutrombopag (JAN/USAN/INN) Drug groups [BR:br08330] Metabolizing enzyme substrate DG02978 CYP4A11 substrate D10476 Lusutrombopag Target-based classification of drugs [BR:br08310] Cytokines and receptors Cytokine receptors CSF and other factor receptors MPL (TPOR, CD110) D10476 Lusutrombopag (JAN/USAN/INN) <JP/US> New drug approvals in the USA [br08319.html] New molecular entities and new therapeutic biological products D10476 New drug approvals in Europe [br08329.html] European public assessment reports (EPAR) authorised medicine D10476 New drug approvals in Japan [br08318.html] Drugs with new active ingredients D10476 New drug approvals in the USA, Europe and Japan [br08328.html] Approval dates by FDA, EMA and PMDA D10476 Drug metabolizing enzymes and transporters [br08309.html] Drug metabolizing enzymes D10476 Pharmacogenomic biomarkers [br08341.html] Polymorphisms and mutations affecting drug response D10476 | ||||||
| Other DBs |
| ||||||
| KCF data | ATOM 39 1 C8y C 13.5100 -30.7300 2 N5x N 14.9100 -30.7300 3 C8y C 15.3300 -29.4000 4 S2x S 14.2100 -28.5600 5 C8x C 13.0900 -29.4000 6 C5a C 17.7800 -29.4000 7 N1b N 16.5900 -28.7000 8 C8y C 18.9700 -28.7000 9 C8x C 20.1600 -29.4000 10 C8y C 21.4200 -28.7000 11 C8y C 21.4200 -27.3000 12 C8y C 20.1600 -26.6000 13 C8x C 18.9700 -27.3000 14 O5a O 17.7800 -30.8000 15 X Cl 22.6100 -29.4000 16 C2b C 22.6100 -26.5300 17 C2c C 23.8000 -27.2300 18 C6a C 24.9900 -26.5300 19 O6a O 24.9900 -25.1300 20 C8y C 12.6700 -31.8500 21 C8x C 11.2700 -31.8500 22 C8x C 10.5700 -33.0400 23 C8x C 11.2700 -34.3000 24 C8y C 12.6700 -34.3000 25 C8y C 13.3700 -33.0400 26 O2a O 14.7700 -33.0400 27 C1a C 15.5400 -34.2300 28 C1c C 13.3700 -35.4900 29 C1a C 14.7700 -35.4900 30 O2a O 12.6700 -36.6800 31 C1b C 11.2700 -36.6800 32 C1b C 10.5700 -37.8700 33 C1b C 9.1700 -37.8700 34 C1b C 8.4700 -39.0600 35 C1b C 7.0700 -39.0600 36 C1a C 6.3700 -40.2500 37 X Cl 20.1428 -25.2001 38 C1a C 23.8000 -28.6300 39 O6a O 26.2053 -27.2251 BOND 41 1 1 2 1 2 2 3 2 3 3 4 1 4 4 5 1 5 1 5 2 6 6 7 1 7 3 7 1 8 6 8 1 9 8 9 2 10 9 10 1 11 10 11 2 12 11 12 1 13 12 13 2 14 8 13 1 15 6 14 2 16 10 15 1 17 11 16 1 18 16 17 2 19 17 18 1 20 18 19 2 21 1 20 1 22 20 21 2 23 21 22 1 24 22 23 2 25 23 24 1 26 24 25 2 27 20 25 1 28 25 26 1 29 26 27 1 30 24 28 1 31 28 29 1 #Down 32 28 30 1 33 30 31 1 34 31 32 1 35 32 33 1 36 33 34 1 37 34 35 1 38 35 36 1 39 12 37 1 40 17 38 1 41 18 39 1 |